Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Buy
67
KNSA Quote, Financials, Valuation and Earnings
Last price:
$44.71
Seasonality move
:
1.74%
Day range:
$43.11 - $44.98
52-week range:
$18.26 - $45.50
Dividend yield:
0%
P/E ratio:
100.33x
P/S ratio:
5.76x
P/B ratio:
6.37x
Volume:
350.5K
Avg. volume:
613K
1-year change:
128.32%
Market cap:
$3.4B
Revenue:
$423.2M
EPS (TTM):
$0.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$200.9M | $0.37 | 52.45% | -62.86% | $55.00 |
|
ABTI
Alterola Biotech, Inc.
|
-- | -- | -- | -- | -- |
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 23.95% | 81.82% | $25.67 |
|
LIVN
LivaNova Plc
|
$354.3M | $0.81 | 6.94% | -20.28% | $73.00 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.19 | -69.71% | -54.94% | $7.87 |
|
NVCR
NovoCure Ltd.
|
$173.4M | -$0.41 | -2.72% | -66.56% | $24.07 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$44.98 | $55.00 | $3.4B | 100.33x | $0.00 | 0% | 5.76x |
|
ABTI
Alterola Biotech, Inc.
|
$0.0051 | -- | $7.4M | -- | $0.00 | 0% | -- |
|
ADMA
ADMA Biologics, Inc.
|
$16.28 | $25.67 | $3.9B | 19.12x | $0.00 | 0% | 8.20x |
|
LIVN
LivaNova Plc
|
$66.43 | $73.00 | $3.6B | 38.16x | $0.00 | 0% | 2.70x |
|
MRKR
Marker Therapeutics, Inc.
|
$1.46 | $7.87 | $24.3M | -- | $0.00 | 0% | 3.96x |
|
NVCR
NovoCure Ltd.
|
$10.50 | $24.07 | $1.2B | -- | $0.00 | 0% | 1.81x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
1.78% | -0.635 | 0.33% | 3.27x |
|
ABTI
Alterola Biotech, Inc.
|
-- | 662.302 | -- | -- |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.277 | 2.38% | 3.53x |
|
LIVN
LivaNova Plc
|
29.6% | 1.643 | 17.01% | 1.05x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 2.330 | -- | 5.66x |
|
NVCR
NovoCure Ltd.
|
70.04% | 0.751 | 55.15% | 1.44x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$97.3M | $24M | 7.44% | 7.6% | 13.28% | $33M |
|
ABTI
Alterola Biotech, Inc.
|
-- | -$477.2K | -- | -- | -- | -$920.6K |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
LIVN
LivaNova Plc
|
$244.9M | $56.6M | -12.15% | -18.29% | 15.83% | $62.2M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
NVCR
NovoCure Ltd.
|
$122.5M | -$36M | -16.67% | -50.08% | -21.54% | $14.9M |
Kiniksa Pharmaceuticals International Plc vs. Competitors
-
Which has Higher Returns KNSA or ABTI?
Alterola Biotech, Inc. has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of --. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat Alterola Biotech, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M ABTIAlterola Biotech, Inc.-- -$0.00 -- -
What do Analysts Say About KNSA or ABTI?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $55.00, signalling upside risk potential of 22.28%. On the other hand Alterola Biotech, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kiniksa Pharmaceuticals International Plc has higher upside potential than Alterola Biotech, Inc., analysts believe Kiniksa Pharmaceuticals International Plc is more attractive than Alterola Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 ABTIAlterola Biotech, Inc.0 0 0 -
Is KNSA or ABTI More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.060, which suggesting that the stock is 94.045% less volatile than S&P 500. In comparison Alterola Biotech, Inc. has a beta of 66.988, suggesting its more volatile than the S&P 500 by 6598.781%.
-
Which is a Better Dividend Stock KNSA or ABTI?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alterola Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. Alterola Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or ABTI?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are larger than Alterola Biotech, Inc. quarterly revenues of --. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is higher than Alterola Biotech, Inc.'s net income of -$691.8K. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 100.33x while Alterola Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.76x versus -- for Alterola Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.76x 100.33x $180.9M $18.4M ABTIAlterola Biotech, Inc.-- -- -- -$691.8K
-
Which has Higher Returns KNSA or ADMA?
ADMA Biologics, Inc. has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of 27.14%. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About KNSA or ADMA?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $55.00, signalling upside risk potential of 22.28%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 57.66%. Given that ADMA Biologics, Inc. has higher upside potential than Kiniksa Pharmaceuticals International Plc, analysts believe ADMA Biologics, Inc. is more attractive than Kiniksa Pharmaceuticals International Plc.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 ADMAADMA Biologics, Inc.3 0 0 -
Is KNSA or ADMA More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.060, which suggesting that the stock is 94.045% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.502%.
-
Which is a Better Dividend Stock KNSA or ADMA?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or ADMA?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are larger than ADMA Biologics, Inc. quarterly revenues of $134.2M. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 100.33x while ADMA Biologics, Inc.'s PE ratio is 19.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.76x versus 8.20x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.76x 100.33x $180.9M $18.4M ADMAADMA Biologics, Inc.8.20x 19.12x $134.2M $36.4M
-
Which has Higher Returns KNSA or LIVN?
LivaNova Plc has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of 7.49%. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat LivaNova Plc's return on equity of -18.29%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M LIVNLivaNova Plc68.44% $0.49 $1.6B -
What do Analysts Say About KNSA or LIVN?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $55.00, signalling upside risk potential of 22.28%. On the other hand LivaNova Plc has an analysts' consensus of $73.00 which suggests that it could grow by 9.89%. Given that Kiniksa Pharmaceuticals International Plc has higher upside potential than LivaNova Plc, analysts believe Kiniksa Pharmaceuticals International Plc is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 LIVNLivaNova Plc6 2 0 -
Is KNSA or LIVN More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.060, which suggesting that the stock is 94.045% less volatile than S&P 500. In comparison LivaNova Plc has a beta of 0.967, suggesting its less volatile than the S&P 500 by 3.292%.
-
Which is a Better Dividend Stock KNSA or LIVN?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LivaNova Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. LivaNova Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or LIVN?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are smaller than LivaNova Plc quarterly revenues of $357.8M. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is lower than LivaNova Plc's net income of $26.8M. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 100.33x while LivaNova Plc's PE ratio is 38.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.76x versus 2.70x for LivaNova Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.76x 100.33x $180.9M $18.4M LIVNLivaNova Plc2.70x 38.16x $357.8M $26.8M
-
Which has Higher Returns KNSA or MRKR?
Marker Therapeutics, Inc. has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of -162.11%. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M -
What do Analysts Say About KNSA or MRKR?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $55.00, signalling upside risk potential of 22.28%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 438.81%. Given that Marker Therapeutics, Inc. has higher upside potential than Kiniksa Pharmaceuticals International Plc, analysts believe Marker Therapeutics, Inc. is more attractive than Kiniksa Pharmaceuticals International Plc.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 MRKRMarker Therapeutics, Inc.3 0 0 -
Is KNSA or MRKR More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.060, which suggesting that the stock is 94.045% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.442, suggesting its more volatile than the S&P 500 by 44.218%.
-
Which is a Better Dividend Stock KNSA or MRKR?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or MRKR?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is higher than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 100.33x while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.76x versus 3.96x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.76x 100.33x $180.9M $18.4M MRKRMarker Therapeutics, Inc.3.96x -- $1.2M -$2M
-
Which has Higher Returns KNSA or NVCR?
NovoCure Ltd. has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of -22.29%. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat NovoCure Ltd.'s return on equity of -50.08%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M NVCRNovoCure Ltd.73.25% -$0.33 $1.1B -
What do Analysts Say About KNSA or NVCR?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $55.00, signalling upside risk potential of 22.28%. On the other hand NovoCure Ltd. has an analysts' consensus of $24.07 which suggests that it could grow by 129.25%. Given that NovoCure Ltd. has higher upside potential than Kiniksa Pharmaceuticals International Plc, analysts believe NovoCure Ltd. is more attractive than Kiniksa Pharmaceuticals International Plc.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 NVCRNovoCure Ltd.4 2 0 -
Is KNSA or NVCR More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.060, which suggesting that the stock is 94.045% less volatile than S&P 500. In comparison NovoCure Ltd. has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.187%.
-
Which is a Better Dividend Stock KNSA or NVCR?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovoCure Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. NovoCure Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or NVCR?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are larger than NovoCure Ltd. quarterly revenues of $167.2M. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is higher than NovoCure Ltd.'s net income of -$37.3M. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 100.33x while NovoCure Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.76x versus 1.81x for NovoCure Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.76x 100.33x $180.9M $18.4M NVCRNovoCure Ltd.1.81x -- $167.2M -$37.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
